Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.76 -1.7%	$1.86	$1.00 ▼ $5.22	$42.15M	0.76	337,457 shs	66,343 shs
DBVT DBV Technologies	$9.40 -4.6%	$9.14	$2.20 ▼ $12.78	$257.46M	-0.63	191,126 shs	22,359 shs
FULC Fulcrum Therapeutics	$6.99 +9.9%	$5.61	$2.32 ▼ $10.13	$377.58M	2.4	958,908 shs	607,057 shs
IPHA Innate Pharma	$1.80 -5.3%	$2.09	$1.29 ▼ $3.51	$165.92M	0.26	187,223 shs	9,046 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	+0.57%	-29.32%	-3.30%	-40.94%
DBVT DBV Technologies	0.00%	+3.30%	+7.18%	+88.38%	+92.11%
FULC Fulcrum Therapeutics	0.00%	+2.04%	+14.22%	+121.90%	+7.70%
IPHA Innate Pharma	0.00%	-5.01%	-17.43%	-11.76%	-10.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELU Celularity	0.0772 of 5 stars	0.0	2.0	0.0	1.7	0.0
DBVT DBV Technologies	3.2503 of 5 stars	3.3	5.0	2.5	2.5	0.6
FULC Fulcrum Therapeutics	0.1436 of 5 stars	1.3	0.0	0.0	2.5	0.0
IPHA Innate Pharma	3.0708 of 5 stars	3.8	5.0	2.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	0.00	N/A	N/A	N/A
DBVT DBV Technologies	2.50	Moderate Buy	$14.75	56.91% Upside
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-10.08% Downside
IPHA Innate Pharma	3.50	Strong Buy	$11.00	511.11% Upside

Current Analyst Ratings Breakdown

Latest CELU, DBVT, IPHA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/24/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.00
3/28/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.50

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$54.22M	0.78	N/A	N/A	$0.37 per share	4.76
DBVT DBV Technologies	$4.15M	62.04	N/A	N/A	$1.42 per share	6.62
FULC Fulcrum Therapeutics	$80M	4.72	N/A	N/A	$4.51 per share	1.55
IPHA Innate Pharma	$21.77M	7.62	N/A	N/A	$0.11 per share	16.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$57.89M	-$2.65	N/A	∞	N/A	-106.77%	-271.88%	-42.82%	7/28/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$0.07	N/A	N/A	N/A	N/A	-0.20%	-0.19%	7/30/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CELU, DBVT, IPHA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q4 2024	CELU Celularity	-$1.50	-$0.59	+$0.91	-$0.59	$5.20 million	$18.13 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	4.07	0.38	0.28
DBVT DBV Technologies	N/A	0.72	0.72
FULC Fulcrum Therapeutics	N/A	28.71	28.71
IPHA Innate Pharma	2.52	2.60	2.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
DBVT DBV Technologies	71.74%
FULC Fulcrum Therapeutics	89.83%
IPHA Innate Pharma	0.16%

Insider Ownership

Company	Insider Ownership
CELU Celularity	22.10%
DBVT DBV Technologies	1.44%
FULC Fulcrum Therapeutics	7.00%
IPHA Innate Pharma	31.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	220	23.95 million	18.66 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	50.20 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.78 million	Not Optionable

CELU, DBVT, IPHA, and FULC Headlines

Recent News About These Companies

Innate Pharma (NASDAQ:IPHA) Stock Price Down 1% - Should You Sell?

June 19 at 12:50 AM | marketbeat.com

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

June 17, 2025 | businesswire.com

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

June 13, 2025 | businesswire.com

Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Update

May 30, 2025 | marketbeat.com

Innate Pharma (NASDAQ:IPHA) Shares Down 1.1% - Time to Sell?

May 28, 2025 | marketbeat.com

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

May 27, 2025 | businesswire.com

ASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibody

May 23, 2025 | fiercebiotech.com

Outcome of Innate Pharma’s 2025 Annual General Meeting

May 23, 2025 | finance.yahoo.com

Outcome of Innate Pharma's 2025 Annual General Meeting

May 23, 2025 | businesswire.com

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

May 23, 2025 | businesswire.com

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

May 19, 2025 | businesswire.com

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

May 15, 2025 | businesswire.com

Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

May 13, 2025 | businesswire.com

Innate Pharma announces conference call and webcast for Q1 2025 business update

May 6, 2025 | businesswire.com

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

April 30, 2025 | businesswire.com

Innate Pharma Unveils Promising Preclinical Data for IPH4502 at AACR 2025

April 29, 2025 | tipranks.com

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

April 29, 2025 | businesswire.com

Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright

April 25, 2025 | markets.businessinsider.com

Innate Pharma Announces €15M Investment by Sanofi

April 24, 2025 | businesswire.com

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

April 23, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU, DBVT, IPHA, and FULC Company Descriptions

Celularity NASDAQ:CELU

$1.76 -0.03 (-1.68%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.76 0.00 (0.00%)

As of 06/20/2025 04:04 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

DBV Technologies NASDAQ:DBVT

$9.40 -0.45 (-4.57%)

Closing price 06/20/2025 03:46 PM Eastern

Extended Trading

$9.59 +0.19 (+2.02%)

As of 06/20/2025 04:48 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Fulcrum Therapeutics NASDAQ:FULC

$6.99 +0.63 (+9.91%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.00 +0.00 (+0.07%)

As of 06/20/2025 05:28 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Innate Pharma NASDAQ:IPHA

$1.80 -0.10 (-5.26%)

Closing price 06/20/2025 03:48 PM Eastern

Extended Trading

$1.77 -0.03 (-1.61%)

As of 06/20/2025 04:48 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time